RFL logo

RAFAEL HOLDINGS INC-CLASS B

RFLNYSE
🏆 #4183 by market capUS Equity
$1.17▼ $0.08 (−6.40%)
Latest quote
🔔
Track RFL
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.4%
7d▼ 7.1%
14d▼ 20.4%
30d▼ 42.9%
ytd▲ 1.7%
1y▼ 13.3%
🏦Market Cap
$61M
Small Cap
📈Revenue Growth (YoY)
33.9%
High Growth
📊Gross Margin
95.1%
High
💵FCF Margin
—
⚖️P/S Ratio
64.2x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.17 – $1.22
52-Week Range
$1.12 – $3.96
Volume (shares)
1,048
Avg Volume (shares)
—
Shares Outstanding
52.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$917,000
Last Q Revenue
$179,000
P/E Ratio
—
P/S Ratio
64.2x
EPS (TTM)
$-0.68
Dividend Yield
—
Dilution (1yr)
+109.7%
RFL logo

RAFAEL HOLDINGS INC-CLASS B

RFL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$917K▲ +44.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.0%▼ −28.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$26M▼ −74.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▲ +137.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.2M▲ +109.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$45M▲ +$39M YoY
StockOtter · stockotter.space

About RAFAEL HOLDINGS INC-CLASS B

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.